Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
84 Dyspepsia Trials
Power is an online platform that helps thousands of Dyspepsia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Brain Stimulation for Gastrointestinal Disorders
Pittsburgh, PennsylvaniaThis trial is testing a non-invasive brain stimulation technique called rTMS on healthy people and those with IBS or FD. The goal is to see if it can help regulate automatic body functions like digestion and heart rate by changing brain activity. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that has been used to treat various neurological and psychiatric conditions, including major depression, migraine-associated headaches, and obsessive-compulsive disorder.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21 - 60
Sex:All
244 Participants Needed
QST for Chronic Pancreatitis
Pittsburgh, PennsylvaniaQuantitative Sensory Testing (QST) is a novel investigative technique used in other pain conditions to evaluate patterns of chronic pain, and in this study will be used to elucidate pain patterns in patients with Chronic Pancreatitis (CP). QST uses a specific series of standardized stimulations to map the pain system. QST has the potential to change and improve the treatment paradigm for patients with CP and may eventually be able to predict response to invasive CP therapies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Pancreatic Surgery, Others
500 Participants Needed
Magnetogastrogram for Gastroparesis
Nashville, TennesseeThere is a tremendous clinical need for a noninvasive technique that can assess gastric electrical activity and would be repeatable without any exposure to radiation. Investigators developed a new technique allowing to use noninvasive methods to assess bioelectrical activity in the gastrointestinal system. This has enabled to characterize the normal and pathologic physiology of the stomach through the use of noninvasive magnetogastrogram (MGG) records. Primary hypothesis for this proposal is that analysis of gastric slow wave uncoupling and propagation in multichannel MGG discriminates between normal and pathological gastric electrical activity. Eventually, investigators envision this research leading to new insights for gastrointestinal conditions such as gastroparesis, functional dyspepsia and chronic idiopathic nausea that would inform clinical management of these debilitating diseases.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:12 - 80
Sex:All
150 Participants Needed
Neurostimulation for Autonomic Dysfunction
Milwaukee, WisconsinDisorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsia, irritable bowel) rather than underlying pathophysiology. Many patients manifest comorbidities suggesting an underlying autonomic nervous system (ANS) dysregulation (palpitations, dizziness, cognitive dysfunction). Unfortunately, due to common features of anxiety and visceral hyperreactivity and lack of obvious pathology, children with DGBI are frequently diagnosed with psychosomatic or 'benign, functional disorders' and treated with empiric antidepressants despite lack of scientific support and risks of serious side effects. Little is known about the underlying brain-gut mechanisms linking these comorbidities. A lack of targeted treatment options naturally follows the paucity of mechanistic data. A dysregulated ANS response circuit via brainstem nuclei is linked to visceral hypersensitivity. As the team's prior research has shown, ANS regulation can be non-invasively measured via several validated indices of cardiac vagal tone. Using the novel vagal efficiency (VE) metric, the investigators have demonstrated inefficient vagal regulation in cyclic vomiting syndrome and pain-related DGBI and that low VE predicts response to non-invasive, auricular percutaneous electrical nerve field stimulation (PENFS) therapy. PENFS targets brainstem vagal afferent pathways and, along with brain-gut interventions such as hypnotherapy, are the only therapies currently proven effective for pediatric DGBI. Individualizing neurostimulation based on sensory thresholds while assessing dynamic ANS reactivity offers a path towards personalized medicine using the most effective therapies to date. This proposal will test the feasibility of an ANS tracking software in assessing real-time, autonomic regulation and providing individualized neurostimulation in children with nausea/vomiting and ANS imbalance.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:11 - 18
Sex:Female
Key Eligibility Criteria
Disqualifiers:Organic Disease, Parenteral Nutrition, Developmental Delays, Others
Must Not Be Taking:Antidepressants
120 Participants Needed
Yoga for Indigestion and Delayed Gastric Emptying
Charlotte, North CarolinaThe purpose of this research study is to assess whether using a yoga-based intervention in practice is feasible (possible) and acceptable to patients with Functional Dyspepsia and/or Gastroparesis (FD-GP).
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
10 Participants Needed
Virtual Reality for Reducing Sedation
Brooklyn, New YorkThe study is a prospective pilot patients aged 21 to 65 undergoing screening colonoscopy or diagnostic upper endoscopy. Patients are administered minimal sedation (2 mg of Versed and 25 mg of Fentanyl) and are given Virtual Reality (VR) goggles to wear for the duration of the procedure. The purpose of this study is to assess the feasibility, effect, and safety of using VR goggles during endoscopic procedures to decrease sedation requirements, enhance patient satisfaction, and reduce recovery time.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:21 - 65
Sex:All
20 Participants Needed
Famotidine + Antacids for Indigestion
Stony Brook, New YorkThe aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Renal Insufficiency, Kidney Failure, Pregnant, Others
Must Not Be Taking:Proton Pump Inhibitors
80 Participants Needed
Tradipitant for Indigestion
Rochester, MinnesotaTo evaluate the effects of tradipitant relative to placebo on gastric motor functions, satiation, and postprandial symptoms in patients with functional dyspepsia.
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:18 - 70
Sex:All
60 Participants Needed
Ondansetron for Indigestion in Diabetics
Rochester, MinnesotaThis trial aims to understand why people with indigestion and diabetes have stomach issues. Researchers will study ondansetron, a medication that prevents nausea, to see its effects on these symptoms. Ondansetron is commonly used to prevent nausea and vomiting, particularly in patients undergoing chemotherapy. The study will look at how ondansetron affects stomach function during different tests and in daily life.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Renal, Hepatic, Neurological, Others
Must Not Be Taking:Opiates, MAO Inhibitors, GLP-1 Agonists, Others
150 Participants Needed
Ketotifen for Childhood Indigestion
Kansas City, MissouriThis trial tests ketotifen, a medication that stabilizes certain immune cells, in children aged 8-17 with functional dyspepsia who haven't responded to standard treatments. Ketotifen aims to reduce inflammation and pain by preventing these cells from releasing harmful substances.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:8 - 17
Sex:All
40 Participants Needed
Cognitive Behavioral Therapy for ARFID
Boston, MassachusettsRandomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant/restrictive food intake disorder (ARFID) with weight loss.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Psychosis, Diabetes, Cancer, Others
Must Not Be Taking:Narcotic Analgesics
50 Participants Needed
Vagal Nerve Stimulation for Indigestion and Gastroparesis
Boston, MassachusettsThis trial tests a treatment that sends mild electrical pulses to the outer ear to help people with stomach issues like functional dyspepsia and gastroparesis. The goal is to see if this can improve communication between the brain and stomach and reduce symptoms. Gastric electrical stimulation (GES) has been proposed as an effective treatment option for patients with gastroparesis that does not respond to other treatments.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Gastric Surgery, Arrhythmias, Epilepsy, Pregnancy, Others
Must Not Be Taking:Illicit Drugs, Opioids
65 Participants Needed
Virtual Reality for Indigestion
Jacksonville, FloridaThis trial is testing whether using virtual reality can help people with functional dyspepsia feel better. Functional dyspepsia causes stomach pain and discomfort, and typical treatments don't always work. Virtual reality might help by distracting and relaxing patients, making their symptoms less noticeable.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Peptic Ulcer, Hepatitis, Pancreatitis, Others
Must Not Be Taking:Opioids
30 Participants Needed
Domperidone for Gastrointestinal Disorders
Houston, TexasThis trial studies how well domperidone works in treating patients aged 16 and older with gastrointestinal disorders. Domperidone helps the stomach move food more effectively by making its muscles contract. This can reduce symptoms like pain, bloating, nausea, and vomiting.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:16+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiac Diagnoses, Liver Failure, Electrolyte Disorders, GI Hemorrhage, Prolactinoma, Others
Must Not Be Taking:Antiarrhythmics, MAO Inhibitors
200 Participants Needed
Zypan for Indigestion
Portland, OregonThe purpose of this study is to determine the effects of a readily available dietary supplement on quality of life and digestion in adults with functional dyspepsia.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 70
Sex:All
64 Participants Needed
OHB-607 for Bronchopulmonary Dysplasia
Columbus, OhioThis trial is testing a new medicine to see if it can prevent a serious lung condition in very premature babies. The goal is to see if this new treatment works better at protecting their lungs and reducing the chances of developing chronic lung disease.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:0 - 24
Sex:All
Key Eligibility Criteria
Disqualifiers:Congenital Malformation, Chromosomal Abnormality, Neurological Disease, Others
338 Participants Needed
DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0/7-28 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:0 - 9
Sex:All
Key Eligibility Criteria
Disqualifiers:Congenital Anomalies, Neurologic Disorders, Others
478 Participants Needed
The purpose of this study is to figure out which commonly used antibiotic, cefoxitin or piperacillin-tazobactam, is better at decreasing the rate of surgical site infections after pancreatoduodenectomy.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
962 Participants Needed
Hydrocortisone for Bronchopulmonary Dysplasia
Columbus, OhioThe Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life. Infants will be randomized to receive hydrocortisone or placebo. This study will determine if hydrocortisone improves infants'survival without moderate or severe BPD and will be associated with improvement in survival without moderate or severe neurodevelopmental impairment at 22 - 26 months corrected age.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:< 30
Sex:All
800 Participants Needed
This trial tests a mix of a steroid and a lung-helping substance on very premature babies to reduce severe lung problems or death. The treatment works by reducing lung inflammation and helping the lungs stay open. Steroids like dexamethasone have been used to treat and prevent chronic lung disease in infants, showing beneficial effects.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:< 48
Sex:All
1160 Participants Needed
Red Cell Transfusions for Premature Infants
Columbus, OhioThe objective of the TOP trial is to determine whether higher hemoglobin thresholds for transfusing ELBW infants resulting in higher hemoglobin levels lead to improvement in the primary outcome of survival and rates of neurodevelopmental impairment (NDI) at 22-26 months of age, using standardized assessments by Bayley.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:< 48
Sex:All
1824 Participants Needed
AOC 1020 for Facioscapulohumeral Muscular Dystrophy
Columbus, OhioA Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:16 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, BMI >35, Bleeding Disorders, Others
Must Not Be Taking:Investigative Medications
90 Participants Needed
Robotic Surgery for Head and Neck Cancer
Columbus, OhioThis pilot clinical trial studies transoral robotic surgery (TORS) in treating patients with benign or malignant tumors of the head and neck. TORS is a less invasive type of surgery for head and neck cancer and may have fewer side effects and improve recovery
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Infection, Previous Head/neck Surgery, Others
600 Participants Needed
AOC 1020 for Facioscapulohumeral Muscular Dystrophy
Columbus, OhioA Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:16 - 70
Sex:All
84 Participants Needed
Sildenafil for Bronchopulmonary Dysplasia
Columbus, OhioThis is a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal Intensive Care Units (NICUs)) with severe bronchopulmonary dysplasia (BPD).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:< 29
Sex:All
120 Participants Needed
Pomalidomide + Chemotherapy for Acute Myeloid Leukemia
Columbus, OhioThis trial is testing if adding pomalidomide to standard chemotherapy can improve treatment for patients with a specific type of newly diagnosed leukemia. Pomalidomide works by cutting off the blood supply to cancer, boosting the immune system, and killing cancer cells. The chemotherapy drugs attack cancer cells in multiple ways. Pomalidomide is related to thalidomide and has shown remarkable activity in patients who did not respond to other treatments.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
50 Participants Needed
Diuretic Therapy for Bronchopulmonary Dysplasia
Cincinnati, OhioBabies who are born prematurely often develop a chronic lung disease called bronchopulmonary dysplasia (BPD). BPD puts babies at higher risk for problems with growth and development. Diuretics, such as furosemide, are frequently used in the management of early BPD). Many clinicians use informal trials of therapy to see if a baby responds to diuretics in the short-term before starting chronic diuretic therapy. Despite frequent use of diuretics, it is unclear how many babies truly respond to therapy and if there are long-term benefits of diuretic treatment. Designing research studies to figure this out has been challenging. The Pragmatic Research on Diuretic Management in Early BPD (PRIMED) study is a feasibility pilot study to help us get information to design a larger trial of diuretic management for BPD. Key questions this study will answer include: (1) Can we use an N-of-1 trial to determine whether a particular baby responds to furosemide? In an N-of-1 trial, a baby is switched between furosemide and placebo to compare that particular infant's response on and off diuretics. It is a more rigorous approach to the informal trials of therapy that are often conducted in clinical care. We hope to learn how many babies have a short-term response to furosemide ("responders"); (2) how many babies will still be on respiratory support at the end of the N-of-1 trial? This will help us determine how many patients would be eligible to randomize to chronic diuretic therapy in the second phase of the larger trail, and (3) if a baby is identified as a short-term responder, how many parents and physicians would be willing to randomize the baby to chronic diuretics (3 months) versus placebo in the longer trial?
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:2 - 10
Sex:All
Key Eligibility Criteria
Disqualifiers:Congenital Anomalies, Electrolyte Imbalance, Others
Must Not Be Taking:Dexamethasone, Hydrocortisone, Long-acting Diuretics
30 Participants Needed
Infigratinib for Achondroplasia
Cincinnati, OhioThis is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in subjects with ACH who previously completed a QED-sponsored interventional study, and potentially in additional subjects who are naïve to infigratinib treatment. Quality of Life assessments for this subject population will also be evaluated. Treatment-naïve subjects must have at least a 6-month period of growth assessment in study QBGJ398-001 (PROPEL) and will be enrolled in this OLE study only after a dose to be explored further is identified in Phase 2 Study QBGJ398-201 and subjects are not otherwise eligible to enroll in another QED-sponsored Phase 2 or Phase 3 ACH study.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:3 - 18
Sex:All
300 Participants Needed
BMN 111 for Achondroplasia
Cincinnati, OhioThis trial is testing BMN111, an injection, in children with Achondroplasia to help them grow taller. BMN111 has shown promise in promoting growth in children with achondroplasia.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:15+
Sex:All
73 Participants Needed
BMN 111 for Achondroplasia
Cincinnati, OhioThe intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6+
Sex:All
119 Participants Needed
Page 1 of 3+
Frequently Asked Questions
How much do Dyspepsia clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Dyspepsia clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Dyspepsia trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Dyspepsia is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Dyspepsia medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Dyspepsia clinical trials ?
Most recently, we added Hyperpolarized Gas MRI for Bronchopulmonary Dysplasia, Surgical Navigation System for Osteoarthritis and Infigratinib for Dwarfism to the Power online platform.